Cinda Biotech (01801) maintains its domestic sales target of RMB 20 billion in 2027.
The Zhitong Finance App learned that UBS released a research report stating that Cinda Biotech (01801) will maintain its domestic sales target of 20 billion yuan in 2027. Furthermore, the company expects to record double-digit growth this year and expects EBITDA to be break-even next year. Meanwhile, the Group's product sales in the first quarter of this year increased 60% year over year to over 17 billion yuan. The bank slightly reduced Cinda Biotech's target price from HK$57.7 to HK$57.4, but maintained a “buy” rating.